PCVX:NSD-Vaxcyte Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 115.5

Change

0.00 (0.00)%

Market Cap

USD 14.16B

Volume

0.84M

Analyst Target

USD 49.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 125.13B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 111.91B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 37.99B
ARGX argenx NV ADR

N/A

USD 33.78B
BGNE BeiGene Ltd

N/A

USD 26.57B
MRNA Moderna Inc

N/A

USD 21.07B
RPRX Royalty Pharma Plc

N/A

USD 16.63B
UTHR United Therapeutics Corporatio..

N/A

USD 16.00B
SMMT Summit Therapeutics PLC

N/A

USD 14.66B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 13.41B

ETFs Containing PCVX

HVAX:CA 4.86 % 0.00 %

N/A

N/A
PTH Invesco DWA Healthcare Mo.. 4.60 % 0.60 %

N/A

USD 0.15B
MEDI Harbor Health Care ETF 3.34 % 0.00 %

N/A

USD 0.01B
SCDS JPMorgan Fundamental Data.. 1.32 % 0.00 %

N/A

USD 6.14M
MMSC First Trust Multi-Manager.. 1.23 % 0.00 %

N/A

USD 0.02B
VRTGX Vanguard Russell 2000 Gro.. 0.99 % 0.00 %

N/A

USD 1.19B
VTWG Vanguard Russell 2000 Gro.. 0.65 % 0.20 %

N/A

USD 0.99B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.51 % 0.00 %

N/A

USD 2.91B
R2US:SW SPDR® Russell 2000 US Sm.. 0.51 % 0.00 %

N/A

USD 3.49B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.51 % 0.00 %

N/A

USD 1.19B
RSSL Global X Funds 0.51 % 0.00 %

N/A

N/A
VRTIX Vanguard Russell 2000 Ind.. 0.50 % 0.00 %

N/A

USD 10.02B
ITWO 0.49 % 0.00 %

N/A

N/A
UWM ProShares Ultra Russell20.. 0.34 % 0.95 %

N/A

USD 0.49B
SCHA Schwab U.S. Small-Cap ETF 0.34 % 0.05 %

N/A

USD 18.48B
XRS2:SW Xtrackers Russell 2000 UC.. 0.33 % 0.00 %

N/A

USD 1.37B
VTWO Vanguard Russell 2000 Ind.. 0.33 % 0.15 %

N/A

USD 11.52B
HDG ProShares Hedge Replicati.. 0.08 % 0.95 %

N/A

USD 0.03B
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

N/A

USD 0.01B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

N/A

N/A
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

N/A

USD 0.46B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 3.37B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 3.37B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

USD 1.37B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

USD 1.37B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 3.42B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

USD 1.19B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 2.91B
GERM 0.00 % 0.00 %

N/A

N/A
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

N/A

USD 0.62B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 83.92% 61% D- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.92% 61% D- 79% B-
Trailing 12 Months  
Capital Gain 146.85% 62% D 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 146.85% 62% D 81% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 35.02% 76% C+ 84% B
Dividend Return 35.02% 75% C 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.80% 61% D- 35% F
Risk Adjusted Return 65.09% 98% N/A 86% B+
Market Capitalization 14.16B 98% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector